Bioactive properties and clinical safety of a novel milk protein peptide

Nutrition Journal

Short Report

Men-Hwei Tsai¹  Olof Mollstedt¹  Helen Chen¹  Mike Iosia²  Richard B Kreider³  Chris Rasmussen³  Geoffrey Hudson⁴  Matt Cooke⁵ 

[1] Ambryx Biotechnology, Inc, Riverside, 92507-2155, CA, USA;Department of Health, Exercise Science, and Secondary Education, Lee University, 37320, Cleveland, TN, USA;Exercise and Sport Nutrition Laboratory, Department of Health & Kinesiology, Texas A&M University College Station, 77843-4243, TX, USA;School of Human Performance and Recreation, University of Southern Mississippi, 39406, Hattiesburg, MS, USA;Schools of Biomedical & Health Sciences, Victoria University, 8001, Melbourne, Victoria, Australia;

关键词: Health;    Cancer;    Neutrophil Lymphocyte Ratio;    Insulin Sensitivity;    Quality of Life;   

DOI  :  10.1186/1475-2891-10-99

 received in 2011-08-11, accepted in 2011-09-26,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundMilk protein fractions and peptides have been shown to have bioactive properties. This preliminary study examined the potential mechanisms of action and clinical safety of novel milk protein peptide (MP).FindingsA novel MP mixture inhibits the tyrosine kinase activity of epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 2 (VEGFR2), and insulin receptor (IR) with IC50 of 9.85 μM, 7.7 μM, and 6.18 μM respectively. In vitro, this multi-kinase inhibitor causes apoptosis in HT-29 colon cancer cells, and in a C. elegans worm study, showed a weak but significant increase in lifespan. A six week double-blind, placebo-controlled study involving 73 healthy volunteers demonstrated that the MP mixture is safe to consume orally. All clinical blood markers remained within normal levels and no clinically significant side effects were reported. There was some evidence of improved insulin sensitivity, neutrophil-to-lymphocyte ratio (NLR), and quality of life assessment of role of physical function.ConclusionsThese data in combination with the observed in vitro anti-cancer properties warrant further clinical studies to investigate this MP mixture as a potential clinical nutrition intervention for improving the quality of life and clinical outcomes in cancer patients.Trial RegistrationNCT01412658

【 授权许可】

CC BY   
© Kreider et al; licensee BioMed Central Ltd. 2011